United StatesHouse Bill 2483HR 2483

SUPPORT for Patients and Communities Reauthorization Act of 2025

Health

23 pages

house
senate
president

Last progress December 1, 2025 (4 weeks ago)

Introduced on March 31, 2025 by Brett Guthrie

Sponsors (2)

House Votes

366 Yea · 9 Not Voting · 57 No — 212 needed

Senate Votes

Passed Unanimous Consent

September 18, 2025 (3 months ago)

Passed Senate without amendment by Unanimous Consent. (consideration: CR S6712)

Presidential Signature

Signed

December 1, 2025 (4 weeks ago)

President of the United States

AI Summary

Text Versions

Text as it was Enrolled Bill

September 20, 2025•23 pages

View

Text as it was Referred in Senate

June 5, 2025•58 pages

View

Text as it was Engrossed in House

June 4, 2025•60 pages

View

Text as it was Reported in House

May 29, 2025•52 pages

View

Text as it was Introduced in House

March 31, 2025•51 pages

View

Amendments

HAMDT 25June 4, 2025An amendment numbered 3 printed in Part A of House Report 119-130 to codify Biden-era guidance to ensure that budget neutrality requirements for Section 1115 Waivers take into account downstream savings.

HAMDT 26June 4, 2025An amendment numbered 4 printed in Part A of House Report 119-130 to require HHS to convene a public meeting to improve awareness of, access to, and information related to funding opportunities related to mental health and SUD programs of SAMHSA grant programs.

HAMDT 24June 4, 2025An amendment numbered 2 printed in Part A of House Report 119-130 to require the Office of the National Coordinator to convene a public roundtable to examine how the expanded use of electronic health records among mental health and substance use service providers can improve outcomes for patients in mental health and substance use disorder settings and how best to increase Electronic Health Record adoption among such providers.

HAMDT 23June 4, 2025An amendment numbered 1 printed in Part A of House Report 119-130 to require all HHS regulations or guidance documentation to use language that is inclusive of all opioid overdose reversal drugs that have been approved by FDA, instead of referring to brand names.